![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Show more
ニュージャージー州における8億ドルの投資により、先進技術を使った製造能力と新たながん治療薬の臨床開発能力を獲得し、グローバルな成長と拡大をサポート (ビジネスワイヤ) -- がん領域専門のグローバル...
800-Millionen-Dollar-Investition in New Jersey unterstützt globales Wachstum und Expansion mit technologisch fortschrittlichen Produktionskapazitäten und klinischen Entwicklungsmöglichkeiten für...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines...
(ビジネスワイヤ) -- グローバル・オンコロジー企業のベイジーン(NASDAQ:BGNE;HKEX:06160;SSE:688235)は、アーロン・ローゼンバーグ氏を7月22日付で最高財務責任者(CFO)に任命したことを発表しまし...
BeiGene, Ltd. (NASDAQ : BGNE ; HKEX : 06160 ; SSE : 688235), société internationale d'oncologie, a annoncé aujourd'hui la nomination d'Aaron Rosenberg au poste de COO, à compter du 22 juillet. M...
(美國商業資訊)-- 全球性腫瘤公司BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235)今日宣布任命Aaron Rosenberg為財務長,自7月22日起生效。Rosenberg先生將接替Julia Wang的職務,後者將從公司離職以尋...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, gab heute die Ernennung von Aaron Rosenberg zum Finanzvorstand mit Wirkung vom 22. Juli bekannt. Aaron...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg...
Le groupe D de l’étude SEQUOIA a évalué des patients naïfs de traitement atteints de leucémie lymphoïde chronique ou de petit lymphome lymphocytaire avec del(17p) à haut risque et/ou avec...
In Arm D der SEQUOIA-Studie wurden unbehandelte Hochrisikopatienten mit chronischer lymphozytischer Leukämie oder kleinzelligem lymphozytischem Lymphom und del(17p) und/oder TP53-Mutation...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions